- Home
- ANGO vs ADCT Comparison
ANGO vs ADCT Comparison
Compare ANGO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- ADCT
- Stock Information
- Founded
- ANGO 1988
- ADCT 2011
- Country
- ANGO United States
- ADCT Switzerland
- Employees
- ANGO N/A
- ADCT N/A
- Industry
- ANGO Medical/Dental Instruments
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- ADCT Health Care
- Exchange
- ANGO Nasdaq
- ADCT Nasdaq
- Market Cap
- ANGO 279.1M
- ADCT 224.3M
- IPO Year
- ANGO 2004
- ADCT 2020
- Fundamental
- Price
- ANGO $11.94
- ADCT $1.76
- Analyst Decision
- ANGO Strong Buy
- ADCT Strong Buy
- Analyst Count
- ANGO 3
- ADCT 5
- Target Price
- ANGO $13.00
- ADCT $8.00
- AVG Volume (30 Days)
- ANGO 849.3K
- ADCT 709.5K
- Earning Date
- ANGO 01-08-2025
- ADCT 03-12-2025
- Dividend Yield
- ANGO N/A
- ADCT N/A
- EPS Growth
- ANGO N/A
- ADCT N/A
- EPS
- ANGO N/A
- ADCT N/A
- Revenue
- ANGO $286,498,000.00
- ADCT $70,717,000.00
- Revenue This Year
- ANGO N/A
- ADCT $6.81
- Revenue Next Year
- ANGO $7.69
- ADCT $11.23
- P/E Ratio
- ANGO N/A
- ADCT N/A
- Revenue Growth
- ANGO N/A
- ADCT N/A
- 52 Week Low
- ANGO $5.26
- ADCT $1.68
- 52 Week High
- ANGO $13.13
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- ANGO 64.64
- ADCT 41.61
- Support Level
- ANGO $11.65
- ADCT $1.68
- Resistance Level
- ANGO $12.96
- ADCT $2.14
- Average True Range (ATR)
- ANGO 0.69
- ADCT 0.14
- MACD
- ANGO 0.16
- ADCT 0.00
- Stochastic Oscillator
- ANGO 72.83
- ADCT 16.35
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.